Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Blood blood.2024025945.

https://doi.org/10.1182/blood.2024025945

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma Trial Eligibility Criteria: A Real-World Multicenter Study

Danai Dima, Aliya Rashid, James A Davis, Hussein Awada, Al-Ola Abdallah, Hong Li, Shaun DeJarnette, Leyla Shune, Jack Khouri, Hamza Hashmi, Joseph P McGuirk, Faiz Anwer, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 4885.

https://doi.org/10.1182/blood-2023-180368

Published: 2023

Journal Articles

Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease

Danai Dima, James A Davis, Aliya Rashid, Mikhaila Rice, Shaun DeJarnette, Leyla Shune, Jack Khouri, Shahzad Raza, Joseph P McGuirk, Faiz Anwer, Nausheen Ahmed, Al-Ola Abdallah, Hamza Hashmi

Blood (2023) 142 (Supplement 1): 4882.

https://doi.org/10.1182/blood-2023-181331

Published: 2023

Journal Articles

Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure

Forat Lutfi, Briha Ansari, Afraah Hawa, Al-Ola Abdallah, Zubair Shah, Andre Khazak, Hussam Hawamdeh, Marc S. Hoffmann, Muhammad Umair Mushtaq, William Wesson, Aliya Rashid, Maggie Nelson, Leyla Shune, Sunil Abhyankar, Joseph P McGuirk, Charles Porter, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6916.

https://doi.org/10.1182/blood-2023-188031

Published: 2023

Journal Articles

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3499.

https://doi.org/10.1182/blood-2023-187565

Published: 2023

Journal Articles

Use of Eltrombopag for Post-CAR T Cytopenias: A Multi-Institutional Experience

William Wesson, Nausheen Ahmed, James A Davis, Mary McGann, Aliya Rashid, Carine Tabak, Emerson Logan, Jose Marchena-Burgos, Maggie Nelson, Leyla Shune, Marc S. Hoffmann, Al-Ola Abdallah, Hamza Hashmi

Blood (2023) 142 (Supplement 1): 2136.

https://doi.org/10.1182/blood-2023-181283

Published: 2023

Journal Articles

Comparison of Biosimilar Filgrastim (Nivestym) Versus Originator Filgrastim (Neupogen) for Peripheral Blood Stem Cell Mobilization for Allogeneic Hematopoietic Stem Cell Transplantation

Moazzam Shahzad, Joe S. Al-Ramahi, Muhammad Kashif Amin, Muhammad Fareed Khalid, Shaun DeJarnette, Zahra Mahmoudjafari, Maggie Nelson, Riley Hastings, Haitham Abdelhakim, Forat Lutfi, Nausheen Ahmed, Rajat Bansal, Leyla Shune, Al-Ola Abdallah, Anurag K. Singh, Sunil Abhyankar, Joseph P McGuirk, Muhammad Umair Mushtaq

Blood (2023) 142 (Supplement 1): 3523.

https://doi.org/10.1182/blood-2023-185652

Published: 2023

Journal Articles

Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post-Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: A Multicenter Phase II Randomized Clinical Trial

Leyla Shune, Ayman Qasrawi, Gerhard Hildebrandt, Eric J Huselton, Howard Langstein, Dennis Allin, Kaitlyn Burrows, Andrea M Baran, Jane L. Liesveld, Neil Blumberg, Brea Lipe, Andrew G Evans, Derick R Peterson, Omar Aljitawi

Blood (2023) 142 (Supplement 1): 2221.

https://doi.org/10.1182/blood-2023-190079

Published: 2023

Journal Articles

Trends in Access to Cellular Therapies in Multiple Myeloma (TACTUM): Perspectives of Treating Versus Referring Physicians

Rawan Atallah, Md Saiful Islam Saif, Danai Dima, Anuj Shrestha, Faiz Anwer, Muhammad Umair Mushtaq, Forat Lutfi, Leyla Shune, Hamza Hashmi, Siddhartha Ganguly, Joseph P McGuirk, Shebli Atrash, Al-Ola Abdallah, Rahul Banerjee, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6678.

https://doi.org/10.1182/blood-2023-181218

Published: 2023

Journal Articles

Outcomes after Bone Marrow Versus Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation

Joe S. Al-Ramahi, Moazzam Shahzad, Muhammad Kashif Amin, Shaun DeJarnette, Maggie Nelson, Forat Lutfi, Nausheen Ahmed, Haitham Abdelhakim, Rajat Bansal, Leyla Shune, Al-Ola Abdallah, Anurag K. Singh, Sunil Abhyankar, Joseph P McGuirk, Muhammad Umair Mushtaq

Blood (2023) 142 (Supplement 1): 7028.

https://doi.org/10.1182/blood-2023-185209

Published: 2023

Journal Articles

Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 3479.

https://doi.org/10.1182/blood-2023-182430

Published: 2023

Journal Articles

Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis

Muhammad Kashif Amin, Moazzam Shahzad, Joe S. Al-Ramahi, Shaun DeJarnette, Forat Lutfi, Nausheen Ahmed, Haitham Abdelhakim, Rajat Bansal, Leyla Shune, Al-Ola Abdallah, Anurag K. Singh, Sunil Abhyankar, Joseph P McGuirk, Muhammad Umair Mushtaq

Blood (2023) 142 (Supplement 1): 2242.

https://doi.org/10.1182/blood-2023-182521

Published: 2023

Journal Articles

Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy

Blood (2023) 142 (Supplement 1): 1063.

https://doi.org/10.1182/blood-2023-178798

Published: 2023

Journal Articles

Vdpace As Salvage Therapy in Triple Class Relapse/Refractory Multiple Myeloma

Priyanka Venkatesh, Sara Shatnawi, Yara Shatnawi, Hira Shaikh, Christopher Strouse, Shebli Atrash, Muhammad Umair Mushtaq, Nausheen Ahmed, Zahra Mahmoudjafari, Al-Ola Abdallah, Leyla Shune

Blood (2023) 142 (Supplement 1): 6694.

https://doi.org/10.1182/blood-2023-187652

Published: 2023

Journal Articles

Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Blood (2023) 142 (Supplement 1): 4880.

https://doi.org/10.1182/blood-2023-187440

Published: 2023

Journal Articles

Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

Moazzam Shahzad, Raheel S Siddiqui, Sakina Abbas, Sibgha Gull Chaudhary, Mamoon Ahmed, Amna Y Shah, Muhammad Arslan, Iqra Anwar, Ramesh Balusu, Rajat Bansal, Nausheen Ahmed, Leyla Shune, Peiman Hematti, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2021) 138 (Supplement 1): 4683.

https://doi.org/10.1182/blood-2021-145505

Published: 2021

Journal Articles

Outcomes with Hematopoietic Stem Cell Transplantation in Secondary Hemophagocytic Lymphohistiocytosis: A Systematic Review and Meta-Analysis

Qamar Iqbal, Moazzam Shahzad, Ezza Tariq, Laila Hashim, Abdul Basit, Kashf Zaidi, Muhammad Salman Faisal, Iqra Anwar, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Leyla Shune, Peiman Hematti, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2021) 138 (Supplement 1): 3963.

https://doi.org/10.1182/blood-2021-149722

Published: 2021

Journal Articles

Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation Following Reduced Intensity Conditioning: A Systematic Review and Meta-Analysis

Moazzam Shahzad, Sibgha Gull Chaudhary, Ezza Tariq, Naira Fatima, Muhammad Arslan, Muhammad Usman Zafar, Amna Y Shah, Mamoon Ahmed, Iqra Anwar, Nausheen Ahmed, Leyla Shune, Ramesh Balusu, Peiman Hematti, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2021) 138 (Supplement 1): 2863.

https://doi.org/10.1182/blood-2021-146051

Published: 2021

Journal Articles

Safety and Cost Effectiveness of Chimeric Antigen Receptor T Cell Therapy in the Outpatient Setting

Moazzam Shahzad, Muhammad Salman Faisal, Ernie Shippey, Ali Hussain, Clint Divine, Zahra Mahmoudjafari, Allison Appenfeller, Muhammad Umair Mushtaq, Leyla Shune, Joseph P. McGuirk, Nausheen Ahmed

Blood (2021) 138 (Supplement 1): 2823.

https://doi.org/10.1182/blood-2021-151872

Published: 2021

Journal Articles

Outcomes with "Off the Shelf" Allogeneic CD19 Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies: A Systematic Review and Meta-Analysis

Muhammad Umair Mushtaq, Moazzam Shahzad, Ali Hussain, Amna Y Shah, Raheel S Siddiqui, Muhammad Salman Faisal, Iqra Anwar, Sibgha Gull Chaudhary, Ghulam Rehman Mohyuddin, Ramesh Balusu, Aung M Tun, Rajat Bansal, Haitham Abdelhakim, Marc Hoffmann, Anurag K. Singh, Leyla Shune, Sunil Abhyankar, Joseph P. McGuirk, Nausheen Ahmed

Blood (2021) 138 (Supplement 1): 4831.

https://doi.org/10.1182/blood-2021-148999

Published: 2021

NARROW

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma Trial Eligibility Criteria: A Real-World Multicenter Study

Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease

Permissive Cardiotoxicity As a Guiding Principle to CAR-T Therapy with Reduced Ejection Fraction Heart Failure

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Use of Eltrombopag for Post-CAR T Cytopenias: A Multi-Institutional Experience

Comparison of Biosimilar Filgrastim (Nivestym) Versus Originator Filgrastim (Neupogen) for Peripheral Blood Stem Cell Mobilization for Allogeneic Hematopoietic Stem Cell Transplantation

Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post-Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: A Multicenter Phase II Randomized Clinical Trial

Trends in Access to Cellular Therapies in Multiple Myeloma (TACTUM): Perspectives of Treating Versus Referring Physicians

Outcomes after Bone Marrow Versus Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation

Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis

Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy

Vdpace As Salvage Therapy in Triple Class Relapse/Refractory Multiple Myeloma

Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

Outcomes with Hematopoietic Stem Cell Transplantation in Secondary Hemophagocytic Lymphohistiocytosis: A Systematic Review and Meta-Analysis

Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation Following Reduced Intensity Conditioning: A Systematic Review and Meta-Analysis

Safety and Cost Effectiveness of Chimeric Antigen Receptor T Cell Therapy in the Outpatient Setting

Outcomes with "Off the Shelf" Allogeneic CD19 Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies: A Systematic Review and Meta-Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only